1-3 of 3
Jordan Fridman, PhD
Close
Sort by
Journal Articles

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben A. Mesa, MD, FACP, William J. Hogan, MBChB, John R. Redman, MD, Sue Erickson-Viitanen, Richard Levy, MD, Kris Vaddi, PhD, DVM, Edward Bradley, MD, Jordan Fridman, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1762.
https://doi.org/10.1182/blood.V112.11.1762.1762
Published: 2008
Journal Articles

INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Animesh Pardanani, MD, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben Mesa, MD, John Redman, MD, Carl-Michael Staschen, MD, PhD, Jordan Fridman, PhD, Kris Vaddi, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2007) 110 (11): 558.
https://doi.org/10.1182/blood.V110.11.558.558
Published: 2007
Journal Articles

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Jordan Fridman, PhD, Roberto Nussenzveig, PhD, Phillip Liu, PhD, James Rodgers, PhD, Timothy Burn, PhD, Patrick Haley, DVM, Peggy Scherle, PhD, Robert Newton, PhD, Gregory Hollis, PhD, Steven Friedman, MD, Srdan Verstovsek, MD, PhD, Kris Vaddi, PhD
Journal: Blood
Blood (2007) 110 (11): 3538.
https://doi.org/10.1182/blood.V110.11.3538.3538
Published: 2007